Brca1 is involved in tolerance to adefovir dipivoxil‑induced DNA damage

  • Authors:
    • Hao Liu
    • Yang Wu
    • Fang He
    • Ziyuan Cheng
    • Zilu Zhao
    • Cuifang Xiang
    • Xiaoyu Feng
    • Xin Bai
    • Shunichi Takeda
    • Xiaohua Wu
    • Yong Qing
  • View Affiliations

  • Published online on: April 11, 2019     https://doi.org/10.3892/ijmm.2019.4164
  • Pages: 2491-2498
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Nucleos(t)ide analogues (NAs) are currently the most important anti‑viral treatment option for patients with chronic hepatitis B (CHB). Adefovir dipivoxil (ADV), a diester pro‑drug of adefovir, has been widely used for the clinical therapy of hepatitis B virus infection. It has been previously reported that adefovir induced chromosomal aberrations (CAs) in the in vitro human peripheral blood lymphocyte assay, while the genotoxic mechanism remains elusive. To evaluate the possible mechanisms, the genotoxic effects of ADV on the TK6 and DT40 cell lines, as well as DNA repair‑deficient variants of DT40 cells, were assessed in the present study. A karyotype assay revealed ADV‑induced CAs, particularly chromosomal breaks, in wild‑type DT40 and TK6 cells. A γ‑H2AX foci formation assay confirmed the presence of DNA damage following treatment with ADV. Furthermore, Brca1‑/‑ DT40 cells exhibited an increased sensitivity to ADV, while the knockdown of various other DNA damage‑associated genes did not markedly affect the sensitivity. These comprehensive genetic studies identified the genotoxic capacity of ADV and suggested that Brca1 may be involved in the tolerance of ADV‑induced DNA damage. These results may contribute to the development of novel drugs against CHB with higher therapeutic efficacy and less genotoxicity.

References

1 

Zhou TC, Li X, Chen LJ, Fan JH, Lai X, Tang Y, Zhang L and Wei J: Differential expression profile of hepatic circular RNAs in chronic hepatitis B. J Viral Hepat. 25:1341–1351. 2018.PubMed/NCBI

2 

Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, et al: Asian-Pacific clinical practice guidelines on the management of hepatitis B: A 2015 update. Hepatol Int. 10:1–98. 2016.

3 

Hu J, Cheng J, Tang L, Hu Z, Luo Y, Li Y, Zhou T, Chang J and Guo JT: Virological basis for the cure of chronic hepatitis B. ACS Infect Dis. 2018.

4 

Yang HC and Kao JH: Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: Molecular mechanisms and clinical significance. Emerg Microbes Infect. 3:e642014.

5 

Zoulim F: New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol. 42:302–308. 2005.PubMed/NCBI

6 

European Association for the Study of the Liver: EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 57:167–185. 2012.PubMed/NCBI

7 

Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM and Murad MH; American Association for the Study of Liver Diseases: AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 63:261–283. 2016.

8 

Lok AS, McMahon BJ, Brown RS Jr, Wong JB, Ahmed AT, Farah W, Almasri J, Alahdab F, Benkhadra K, Mouchli MA, et al: Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis. Hepatology. 63:284–306. 2016.

9 

European Association for the Study of the Liver: Electronic address easloffice@easloffice.eu; European Association for the Study of the Liver: EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 67:370–398. 2017.

10 

Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr, Bzowej NH and Wong JB: Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 67:1560–1599. 2018.PubMed/NCBI

11 

Tong S and Revill P: Overview of hepatitis B viral replication and genetic variability. J Hepatol. 64(Suppl 1): S4–S16. 2016. View Article : Google Scholar : PubMed/NCBI

12 

Ghany MG: Current treatment guidelines of chronic hepatitis B: The role of nucleos(t)ide analogues and peginterferon. Best Pract Res Clin Gastroenterol. 31:299–309. 2017. View Article : Google Scholar : PubMed/NCBI

13 

Lai CL, Wong D, Ip P, Kopaniszen M, Seto WK, Fung J, Huang FY, Lee B, Cullaro G, Chong CK, et al: Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B. J Hepatol. 66:275–281. 2017. View Article : Google Scholar

14 

Nassal M: HBV cccDNA: Viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut. 64:1972–1984. 2015. View Article : Google Scholar : PubMed/NCBI

15 

Tacke F and Kroy DC: Treatment for hepatitis B in patients with drug resistance. Ann Transl Med. 4:3342016. View Article : Google Scholar : PubMed/NCBI

16 

Jiang L, Wu X, He F, Liu Y, Hu X, Takeda S and Qing Y: Genetic evidence for genotoxic effect of entecavir, an anti-Hepatitis B virus nucleotide analog. PLoS One. 11:e01474402016. View Article : Google Scholar : PubMed/NCBI

17 

Choi J, Kim HJ, Lee J, Cho S, Ko MJ and Lim YS: Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: A Korean nationwide cohort study. JAMA Oncol. 5:30–36. 2018. View Article : Google Scholar : PubMed/NCBI

18 

Cartus A and Schrenk D: Current methods in risk assessment of genotoxic chemicals. Food Chem Toxicol. 106:574–582. 2017. View Article : Google Scholar

19 

US Food Drug Administration: Draft guidance on Adefovir Dipivoxil. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM136541.pdfurisimplehttps://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM136541.pdf.

20 

Baba TW, Giroir BP and Humphries EH: Cell lines derived from avian lymphomas exhibit two distinct phenotypes. Virology. 144:139–151. 1985. View Article : Google Scholar : PubMed/NCBI

21 

Bryce SM, Bemis JC, Avlasevich SL and Dertinger SD: In vitro micronucleus assay scored by flow cytometry provides a comprehensive evaluation of cytogenetic damage and cytotoxicity. Mutat Res. 630:78–91. 2007. View Article : Google Scholar : PubMed/NCBI

22 

Ellinger-Ziegelbauer H, Fostel JM, Aruga C, Bauer D, Boitier E, Deng S, Dickinson D, Le Fevre AC, Fornace AJ Jr, Grenet O, et al: Characterization and interlaboratory comparison of a gene expression signature for differentiating genotoxic mechanisms. Toxicol Sci. 110:341–352. 2009. View Article : Google Scholar : PubMed/NCBI

23 

Fellows MD and O'Donovan MR: Etoposide, cadmium chloride, benzo[a]pyrene, cyclophosphamide and colchicine tested in the in vitro mammalian cell micronucleus test (MNvit) in the presence and absence of cytokinesis block using L5178Y mouse lymphoma cells and 2-aminoanthracene tested in MNvit in the absence of cytokinesis block using TK6 cells at AstraZeneca UK, in support of OECD draft Test Guideline 487. Mutat Res. 702:163–170. 2010. View Article : Google Scholar

24 

Platel A, Nesslany F, Gervais V and Marzin D: Study of oxidative DNA damage in TK6 human lymphoblastoid cells by use of the in vitro micronucleus test: Determination of no-observed-effect levels. Mutat Res. 678:30–37. 2009. View Article : Google Scholar : PubMed/NCBI

25 

Sonoda E, Okada T, Zhao GY, Tateishi S, Araki K, Yamaizumi M, Yagi T, Verkaik NS, van Gent DC, Takata M and Takeda S: Multiple roles of Rev3, the catalytic subunit of polzeta in maintaining genome stability in vertebrates. EMBO J. 22:3188–3197. 2003. View Article : Google Scholar : PubMed/NCBI

26 

Okada T, Sonoda E, Yamashita YM, Koyoshi S, Tateishi S, Yamaizumi M, Takata M, Ogawa O and Takeda S: Involvement of vertebrate polkappa in Rad18-independent postreplication repair of UV damage. J Biol Chem. 277:48690–48695. 2002. View Article : Google Scholar : PubMed/NCBI

27 

Masson M, Niedergang C, Schreiber V, Muller S, Menissier- de Murcia J and de Murcia G: XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol Cell Biol. 18:3563–3571. 1998. View Article : Google Scholar : PubMed/NCBI

28 

Qing Y, Yamazoe M, Hirota K, Dejsuphong D, Sakai W, Yamamoto KN, Bishop DK, Wu X and Takeda S: The epistatic relationship between BRCA2 and the other RAD51 mediators in homologous recombination. PLoS Genet. 7:e10021482011. View Article : Google Scholar : PubMed/NCBI

29 

Takata M, Sasaki MS, Sonoda E, Morrison C, Hashimoto M, Utsumi H, Yamaguchi-Iwai Y, Shinohara A and Takeda S: Homologous recombination and non-homologous end-joining pathways of DNA double-strand break repair have overlapping roles in the maintenance of chromosomal integrity in vertebrate cells. EMBO J. 17:5497–5508. 1998. View Article : Google Scholar : PubMed/NCBI

30 

Rosen EM: BRCA1 in the DNA damage response and at telomeres. Front Genet. 4:852013. View Article : Google Scholar : PubMed/NCBI

31 

Carmichael J, DeGraff WG, Gazdar AF, Minna JD and Mitchell JB: Evaluation of a tetrazolium-based semiautomated colorimetric assay: Assessment of chemosensitivity testing. Cancer Res. 47:936–942. 1987.PubMed/NCBI

32 

Hu X, Wu X, Liu H, Cheng Z, Zhao Z, Xiang C, Feng X, Takeda S and Qing Y: Genistein-induced DNA damage is repaired by nonhomologous end joining and homologous recombination in TK6 cells. J Cell Physiol. 234:2683–2692. 2019. View Article : Google Scholar

33 

Mosmann T: Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods. 65:55–63. 1983. View Article : Google Scholar : PubMed/NCBI

34 

Sonoda E, Sasaki MS, Buerstedde JM, Bezzubova O, Shinohara A, Ogawa H, Takata M, Yamaguchi-Iwai Y and Takeda S: Rad51-deficient vertebrate cells accumulate chromosomal breaks prior to cell death. EMBO J. 17:598–608. 1998. View Article : Google Scholar : PubMed/NCBI

35 

An international system for human cytogenetic nomenclature 1978 ISCN 1978 Report of the standing commitee on human cytogenetic nomenclature. Cytogenet Cell Genet. 21:309–409. 1978.

36 

Yamamoto KN, Hirota K, Kono K, Takeda S, Sakamuru S, Xia M, Huang R, Austin CP, Witt KL and Tice RR: Characterization of environmental chemicals with potential for DNA damage using isogenic DNA repair-deficient chicken DT40 cell lines. Environ Mol Mutagen. 52:547–561. 2011. View Article : Google Scholar : PubMed/NCBI

37 

Ji K, Kogame T, Choi K, Wang X, Lee J, Taniguchi Y and Takeda S: A novel approach using DNA-repair-deficient chicken DT40 cell lines for screening and characterizing the genotoxicity of environmental contaminants. Environ Health Perspect. 117:1737–1744. 2009. View Article : Google Scholar

38 

Dickey JS, Redon CE, Nakamura AJ, Baird BJ, Sedelnikova OA and Bonner WM: H2AX: Functional roles and potential applications. Chromosoma. 118:683–692. 2009. View Article : Google Scholar : PubMed/NCBI

39 

Liu Y, Wu X, Hu X, Chen Z, Liu H, Takeda S and Qing Y: Multiple repair pathways mediate cellular tolerance to resveratrol-induced DNA damage. Toxicol In Vitro. 42:130–138. 2017. View Article : Google Scholar : PubMed/NCBI

40 

Ibuki Y and Toyooka T: Evaluation of chemical phototoxicity, focusing on phosphorylated histone H2AX. J Radiat Res. 56:220–228. 2015. View Article : Google Scholar :

41 

Solovjeva L, Firsanov D, Pleskach N and Svetlova M: Immunofluorescence analysis of gamma-H2AX Foci in mammalian fibroblasts at different phases of the cell cycle. Methods Mol Biol. 1644:187–194. 2017. View Article : Google Scholar

42 

Scully R and Livingston DM: In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature. 408:429–432. 2000. View Article : Google Scholar : PubMed/NCBI

43 

Tarapore P, Hanashiro K and Fukasawa K: Analysis of centrosome localization of BRCA1 and its activity in suppressing centrosomal aster formation. Cell Cycle. 11:2931–2946. 2012. View Article : Google Scholar : PubMed/NCBI

44 

Pathania S, Bade S, Le Guillou M, Burke K, Reed R, Bowman-Colin C, Su Y, Ting DT, Polyak K, Richardson AL, et al: BRCA1 haploinsufficiency for replication stress suppression in primary cells. Nat Commun. 5:54962014. View Article : Google Scholar : PubMed/NCBI

45 

Moynahan ME, Chiu JW, Koller BH and Jasin M: Brca1 controls homology-directed DNA repair. Mol Cell. 4:511–518. 1999. View Article : Google Scholar : PubMed/NCBI

46 

Turner N, Tutt A and Ashworth A: Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer. 4:814–819. 2004. View Article : Google Scholar : PubMed/NCBI

47 

Prakash R, Zhang Y, Feng W and Jasin M: Homologous recombination and human health: The roles of BRCA1, BRCA2, and associated proteins. Cold Spring Harb Perspect Biol. 7:a0166002015. View Article : Google Scholar : PubMed/NCBI

48 

Chen L, Nievera CJ, Lee AY and Wu X: Cell cycle-dependent complex formation of BRCA1.CtIP.MRN is important for DNA double-strand break repair. J Biol Chem. 283:7713–7720. 2008. View Article : Google Scholar : PubMed/NCBI

49 

Sartori AA, Lukas C, Coates J, Mistrik M, Fu S, Bartek J, Baer R, Lukas J and Jackson SP: Human CtIP promotes DNA end resection. Nature. 450:509–514. 2007. View Article : Google Scholar : PubMed/NCBI

50 

Yu X, Wu LC, Bowcock AM, Aronheim A and Baer R: The C-terminal (BRCT) domains of BRCA1 interact in vivo with CtIP, a protein implicated in the CtBP pathway of transcriptional repression. J Biol Chem. 273:25388–25392. 1998. View Article : Google Scholar : PubMed/NCBI

51 

Bunting SF, Callén E, Wong N, Chen HT, Polato F, Gunn A, Bothmer A, Feldhahn N, Fernandez-Capetillo O, Cao L, et al: 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell. 141:243–254. 2010. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

June 2019
Volume 43 Issue 6

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Liu, H., Wu, Y., He, F., Cheng, Z., Zhao, Z., Xiang, C. ... Qing, Y. (2019). Brca1 is involved in tolerance to adefovir dipivoxil‑induced DNA damage. International Journal of Molecular Medicine, 43, 2491-2498. https://doi.org/10.3892/ijmm.2019.4164
MLA
Liu, H., Wu, Y., He, F., Cheng, Z., Zhao, Z., Xiang, C., Feng, X., Bai, X., Takeda, S., Wu, X., Qing, Y."Brca1 is involved in tolerance to adefovir dipivoxil‑induced DNA damage". International Journal of Molecular Medicine 43.6 (2019): 2491-2498.
Chicago
Liu, H., Wu, Y., He, F., Cheng, Z., Zhao, Z., Xiang, C., Feng, X., Bai, X., Takeda, S., Wu, X., Qing, Y."Brca1 is involved in tolerance to adefovir dipivoxil‑induced DNA damage". International Journal of Molecular Medicine 43, no. 6 (2019): 2491-2498. https://doi.org/10.3892/ijmm.2019.4164